ChristophJohnSayedMD

Dermatology • Chapel Hill, NC

Professor of Dermatology

Join to view full profile

Dr. Sayed is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Sayed's full profile

Already have an account?

Office
101 Manning Dr
Department of Internal Medicine
Chapel Hill, NC 27514
Phone+1 919-966-1072

Fax+1 919-843-2356

Education & Training

University of North Carolina HospitalsResidency, Dermatology, 2010 - 2013
University of North Carolina HospitalsInternship, Internal Medicine, 2009 - 2010
University of North Carolina at Chapel Hill School of MedicineClass of 2009

Certifications & Licensure

NC State Medical License 2009 - 2025
American Board of Dermatology Dermatology

Clinical Trials

A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa. Start of enrollment: 2016 Jun 01
Completed
Not Applicable

Publications & Presentations

PubMed

14 citations
Genetic Variants Associated With Hidradenitis Suppurativa.
Quan Sun, K Alaine Broadaway, Sharon N Edmiston, Kristen Fajgenbaum, Tyne Miller-Fleming
JAMA Dermatology. 2023-09-01
4 citations
Hidradenitis Suppurativa in Older Adults.
Franklin R Blum, Bailey M DeBarmore, Christopher J Sayed
JAMA Dermatology. 2023-02-01
19 citations
Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa.
Thrasivoulos Tzellos, Kelsey R van Straalen, Athanassios Kyrgidis, Afsaneh Alavi, Noah Goldfarb
Journal of the European Academy of Dermatology and Venereology. 2023-02-01

Books/Book Chapters

Reichel’s Care for the Elderly, 7th ed.
Chapter: Geriatric Dermatology
Sayed C, Varman K.Editors: Busby-Whitehead J, Arenson C.. Cambridge University Press, New York2016
Frontiers in Gastrointestinal Research.
Chapter: Psoriasis-like Lesions and Skin Reactions (Chapter). In Anti-Tumour Necrosis Factor Therapy in Inflammatory Bowel Disease.
Page 119 - 125Herfarth H, Long M, Sayed C.Editors: Rogler G, Herfarth H, Toshifumi H, Nielsen OH..KargerEdition 34,2015
Pathology: A Modern Case Study.
Chapter: Pathology of the Skin
Miedema J, Sayed C, Zedek D.Editors: Reisner, H..McGraw-Hill. , New YorkEdition 1,2014

Lectures

Advanced Management Strategies for Hidradenitis Suppurativa
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/2/2019
Development of the North American Clinical Guidelines for Hidradenitis Suppurativa
American Academy of Dermatology Annual Meeting, Orlando, FL. - 2/2018
Office-Based Procedures for Hidradenitis Suppurativa
American Academy of Dermatology Annual Meeting, Orlando, FL - 2/2018

Press Mentions

Diagnosing Mild Hidradenitis Suppurativa: Early Stage Can Mimic Other DiseasesMay 21st, 2024

Research History

Co-investigatorA Phase 4, Double-Blind, Randomised,Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction with Surgery in Subjects with Moderate to Severe Hidradenitis Suppurativa.2018 - Present
Principal InvestigatorGenome-wide association study of patients with hidradenitis suppurativa.2018 - Present
Principal Investigator• UCB Biopharma SPRL, HS0001, A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study Of The Efficacy, Safety, And Pharmacokinetics Of Bimekizumab In Subjects With Moderate To Severe Hidradenitis Suppurativa (HS).2018 - Present
Principal InvestigatorA randomized, double-blind, placebo-controlled, multicenter Phase II study to determine efficacy and safety of IFX-1 in subjects with moderate to severe hidradenitis suppurativa (SHINE). 2018.2018 - Present
Co-investigatorA Phase 2, Multi-Center, Evaluator-Blind, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-118 Lotion to Ultravate® (halobetasol propionate) Cream, 0.05% in the Treatment of Plaque Psoriasis.2017 - Present
Co-investigatorAn Observational, Multicenter Disease Registry to Evaluate Clinical Practice Trends and Outcomes in Adult Patients with Hidradenitis Suppurativa.2014 - Present
Co-investigatorA 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator's Global Assessment after 12 weeks of treatment, compared to ustekinumab, and to assess long term safety, tolerability, and efficac2016 - 2018
Principal InvestigatorFull transcriptome analysis in lesional and non-lesional skin of hidradenitis suppurativa with intention to identify disease signatures and understand molecular mechanism of disease.2016 - 2018
Co-investigatorSafety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis2017 - 2017
Principal InvestigatorA randomized, controlled, double blind study to evaluate the efficacy of intralesional triamcinolone in the treatment of hidradenitis suppurativa.2016 - 2017
Co-investigatorA Phase IIa, Randomized, double-blind, placebo-controlled, multicenter study to assess the safety, tolerability and preliminary efficacy of MEDI8968 in Subjects with Moderate to Severe Hidradenitis Suppurativa (HS).2014 - 2015